The Therapeutic Goods Administration (TGA) has given approval for a fourth COVID-19 vaccine.
The Novavax vaccine will be available to people 18 years and over. It will be given in 2 doses, 3 weeks apart.
The Novavax vaccine is a protein subunit vaccine. Protein vaccines use a non-infectious component of the coronavirus. After vaccination, immune cells recognise the vaccine protein as foreign and launch an immune response.
For more information, see the TGA’s media release (20 Jan 2022).